TLSI

TriSalus Life Sciences, Inc. (TLSI) SWOT Analysis Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-08-01

Strengths

Liquidity is strong, with a current ratio of 5.35 and quick ratio of 4.97, giving TLSI more near-term flexibility than more levered peers.

Net debt to EBITDA of 0.55 suggests modest balance-sheet leverage, which is structurally safer than highly indebted competitors in cyclical or capital-intensive niches.

Weaknesses

Return on invested capital of -59.2% indicates capital is destroying value, leaving TLSI structurally weaker than peers that compound returns above their cost of capital.

Debt to equity of 5.26 is elevated, so financing risk remains materially higher than peers with cleaner capital structures despite the current liquidity cushion.

Cash conversion cycle of 77.5 days ties up working capital longer than efficient peers, which constrains reinvestment capacity and margin resilience.

Missing operating and gross margin disclosure limits transparency, but the available profitability signal still points to a weaker operating model than better-performing peers.

Opportunities

If working capital turns faster, the 77.5-day cash conversion cycle could release cash and improve flexibility relative to peers with tighter operating cycles.

Balance-sheet deleveraging could amplify equity value creation because TLSI starts from moderate net leverage, unlike peers already constrained by heavier debt loads.

Threats

Persistent negative ROIC threatens long-term competitive positioning because peers with positive capital returns can reinvest faster and widen structural gaps.

High debt-to-equity increases sensitivity to earnings volatility, making TLSI more vulnerable than less levered peers if operating performance weakens further.

A long cash conversion cycle raises funding needs and can pressure liquidity more than peers with faster inventory and receivables turnover.

Overall Score

TLSI’s liquidity and modest net leverage provide some resilience, but deeply negative ROIC and elevated debt burden leave its structural positioning weaker than peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on TriSalus Life Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →